Improving Person Re-identification by Attribute and Identity Learning

Person re-identification (re-ID) and attribute recognition share a common target at learning pedestrian descriptions. Their difference consists in the granularity. Most existing re-ID methods only take identity labels of pedestrians into consideration. However, we find the attributes, containing detailed local descriptions, are beneficial in allowing the re-ID model to learn more discriminative feature representations. In this paper, based on the complementarity of attribute labels and ID labels, we propose an attribute-person recognition (APR) network, a multi-task network which learns a re-ID embedding and at the same time predicts pedestrian attributes. We manually annotate attribute labels for two large-scale re-ID datasets, and systematically investigate how person re-ID and attribute recognition benefit from each other. In addition, we re-weight the attribute predictions considering the dependencies and correlations among the attributes. The experimental results on two large-scale re-ID benchmarks demonstrate that by learning a more discriminative representation, APR achieves competitive re-ID performance compared with the state-of-the-art methods. We use APR to speed up the retrieval process by ten times with a minor accuracy drop of 2.92% on Market-1501. Besides, we also apply APR on the attribute recognition task and demonstrate improvement over the baselines.Comment: Accepted to Pattern Recognition (PR

Heterologous protein display on the cell surface of lactic acid bacteria mediated by the s-layer protein

<p>Abstract</p> <p>Background</p> <p>Previous studies have revealed that the C-terminal region of the S-layer protein from <it>Lactobacillus </it>is responsible for the cell wall anchoring, which provide an approach for targeting heterologous proteins to the cell wall of lactic acid bacteria (LAB). In this study, we developed a new surface display system in lactic acid bacteria with the C-terminal region of S-layer protein SlpB of <it>Lactobacillus crispatus </it>K2-4-3 isolated from chicken intestine.</p> <p>Results</p> <p>Multiple sequence alignment revealed that the C-terminal region (LcsB) of <it>Lb. crispatus </it>K2-4-3 SlpB had a high similarity with the cell wall binding domains S_Aand CbsA of <it>Lactobacillus acidophilus </it>and <it>Lb. crispatus</it>. To evaluate the potential application as an anchoring protein, the green fluorescent protein (GFP) or beta-galactosidase (Gal) was fused to the N-terminus of the LcsB region, and the fused proteins were successfully produced in <it>Escherichia coli</it>, respectively. After mixing them with the non-genetically modified lactic acid bacteria cells, the fused GFP-LcsB and Gal-LcsB were functionally associated with the cell surface of various lactic acid bacteria tested. In addition, the binding capacity could be improved by SDS pretreatment. Moreover, both of the fused proteins could simultaneously bind to the surface of a single cell. Furthermore, when the fused DNA fragment of <it>gfp:lcsB </it>was inserted into the <it>Lactococcus lactis </it>expression vector pSec:Leiss:Nuc, the GFP could not be secreted into the medium under the control of the <it>nisA </it>promoter. Western blot, in-gel fluorescence assay, immunofluorescence microscopy and SDS sensitivity analysis confirmed that the GFP was successfully expressed onto the cell surface of <it>L. lactis </it>with the aid of the LcsB anchor.</p> <p>Conclusion</p> <p>The LcsB region can be used as a functional scaffold to target the heterologous proteins to the cell surfaces of lactic acid bacteria <it>in vitro </it>and <it>in vivo</it>, and has also the potential for biotechnological application.</p

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) : part two

Background The immunological escape of tumors represents one of the main ob- stacles to the treatment of malignancies. The blockade of PD-1 or CTLA-4 receptors represented a milestone in the history of immunotherapy. However, immune checkpoint inhibitors seem to be effective in specific cohorts of patients. It has been proposed that their efficacy relies on the presence of an immunological response. Thus, we hypothesized that disruption of the PD-L1/PD-1 axis would synergize with our oncolytic vaccine platform PeptiCRAd. Methods We used murine B16OVA in vivo tumor models and flow cytometry analysis to investigate the immunological background. Results First, we found that high-burden B16OVA tumors were refractory to combination immunotherapy. However, with a more aggressive schedule, tumors with a lower burden were more susceptible to the combination of PeptiCRAd and PD-L1 blockade. The therapy signifi- cantly increased the median survival of mice (Fig. 7). Interestingly, the reduced growth of contralaterally injected B16F10 cells sug- gested the presence of a long lasting immunological memory also against non-targeted antigens. Concerning the functional state of tumor infiltrating lymphocytes (TILs), we found that all the immune therapies would enhance the percentage of activated (PD-1pos TIM- 3neg) T lymphocytes and reduce the amount of exhausted (PD-1pos TIM-3pos) cells compared to placebo. As expected, we found that PeptiCRAd monotherapy could increase the number of antigen spe- cific CD8+ T cells compared to other treatments. However, only the combination with PD-L1 blockade could significantly increase the ra- tio between activated and exhausted pentamer positive cells (p= 0.0058), suggesting that by disrupting the PD-1/PD-L1 axis we could decrease the amount of dysfunctional antigen specific T cells. We ob- served that the anatomical location deeply influenced the state of CD4+ and CD8+ T lymphocytes. In fact, TIM-3 expression was in- creased by 2 fold on TILs compared to splenic and lymphoid T cells. In the CD8+ compartment, the expression of PD-1 on the surface seemed to be restricted to the tumor micro-environment, while CD4 + T cells had a high expression of PD-1 also in lymphoid organs. Interestingly, we found that the levels of PD-1 were significantly higher on CD8+ T cells than on CD4+ T cells into the tumor micro- environment (p < 0.0001). Conclusions In conclusion, we demonstrated that the efficacy of immune check- point inhibitors might be strongly enhanced by their combination with cancer vaccines. PeptiCRAd was able to increase the number of antigen-specific T cells and PD-L1 blockade prevented their exhaus- tion, resulting in long-lasting immunological memory and increased median survival

A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors

Abstract Objective. To evaluate the risk factors associated with recurrence of borderline ovarian tumors that may be used as evidence of the efficacy of select preventive procedures. Methods. Various clinicopathologic factors of 234 patients with borderline ovarian tumors admitted to our hospital between January 2001 and June 2007 were reviewed. Univariate and multivariate logistic regression models were constructed to evaluate the risk factors for odds ratio (OR) and statistical significance. The survival was assessed by the Kaplan-Meier method and proportional hazards model. Results. Recurrence of borderline ovarian tumors was observed in 26 cases and the median time to recurrence was 29.4 months. Of these cases, 5 occurred involving the ipsilateral ovary, 9 involved the contralateral ovary, and 12 spread to the pelvic peritoneum, including 3 patients who had progressed to invasive carcinoma. No tumor-related deaths were reported. The results of the multivariate logistic regression analysis showed that conservative surgical procedures (OR = 2.304; p = 0.024), cyst rupture (OR = 2.213; p = 0.038), advanced FIGO stage (OR = 4.114; p = 0.000), microinvasion (OR = 2.291; p = 0.046), and peritoneal implants (OR = 2.101; p = 0.016) may be independent predictive factors of recurrence. The proportional hazards model identified surgical procedure (relative risk, RR = 3.752, p = 0.007), cyst rupture (RR = 1.985, p = 0.006), FIGO stage (RR = 3.746, p = 0.001), microinvasion (RR = 1.153, p = 0.009) and peritoneal implants (RR = 2.742, p = 0.010), as independently related to disease-free survival. Conclusions. Although patients with borderline ovarian tumors have an excellent prognosis, the risk of recurrence remains. Identification of patients with high-risk factors is essential for offering more selective treatments to prevent recurrence